艾塞那肽治疗2型糖尿病的疗效及安全性

摘要

Objective To evaluate the efficacy of exenatide on type 2 diabetic patients. Methods 31 patients with type 2 diabetes mellitus received exenatide therapy at least 12 months. The basal therapeutic measures were not changed. Results After 12 months treatment,FPG,2hPG and HbAlc level reduced( P <0. 05 ). HOMA-IR had gradually reduced( P =0. 05 ),HOMA-B was rising significantly( P <0. 001 ). The weight and BMI of the patients decreased gradually, most obviously in three month. Only TG decreased significantly( P <0. 05 ). No hypoglycemia and pancreatitis occurred. Conclusion Patients with type 2 diabetes mellitus can achieve optimal glycemic level with exenatide therapy, and exenatide can decrease the body weight.%目的 观察对2型糖尿病患者在应用原有降糖药物血糖控制不佳的情况下,加用艾塞那肽的疗效.方法 31例血糖控制不佳的2型糖尿病患者加用艾塞那肽治疗,共随访至12个月.患者原有降压、降脂等治疗方案均不变.结果 从基线到治疗后12个月,患者FPG、2hPG和HbA1c均进行性下降( P <0.001),HOMA-IR指数进行性下降( P <0.05),HOMA-β在用药前6个月变化无统计学意义,而12个月时明显升高( P <0.001).患者治疗期间体重和BMI进行性下降,3个月时变化最明显( P <0.05).血脂中仅TG有显著下降( P <0.05).结论 GLP-1类似物应用于血糖控制不佳的2型糖尿病患者,可以有效地达到血糖控制目标,同时可以达到控制体重的目的.